Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care

Subodh Verma, Eric Klug, Viacheslav Y. Mareev, Zhanna D. Kobalava, Kim A. Connelly, Mustafa Arici, Otávio Berwanger, Anwar Santoso, Roopa Mehta, Gus Meglis, Mikhail N. Kosiborod

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE OF REVIEW: The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. SUMMARY: Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.

Original languageEnglish
Pages (from-to)589-601
Number of pages13
JournalCurrent Opinion in Cardiology
Volume35
Issue number5
DOIs
Publication statusPublished - 1 Sep 2020

Fingerprint

Dive into the research topics of 'Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care'. Together they form a unique fingerprint.

Cite this